Botox Training Little Rock
                     Comprehensive Guide to Botulinum Toxin 
Injection Training
The History of Botulinum Toxin
The history of Botulinum Toxin, often referred to as “botox”, is a fascinating 
journey that spans over several decades. This potent neurotoxin, produced by 
the bacterium Clostridium botulinum, has found its place in the world of cosmetic 
dermatology, offering a non-surgical solution to a variety of aesthetic concerns.
The discovery of Botulinum Toxin dates back to the 19th century when a German
physician, Justinus Kerner, first identified it while investigating a series of food 
poisoning cases. Kerner coined the term “botulism” from the Latin word for 
sausage, “botulus,” as the affected individuals had consumed improperly 
prepared sausages. He was the first to recognize the paralytic symptoms of 
botulism and postulated the existence of a “fatty poison” that interfered with the 
transmission of nerve impulses.
In the early 20th century, Emile Pierre van Ermengem, a Belgian bacteriologist, 
isolated the bacterium we now know as Clostridium botulinum. He discovered 
that the bacterium produced a toxin that caused the symptoms of botulism. This 
marked the first step in understanding the nature of this potent neurotoxin.
The therapeutic potential of Botulinum Toxin was not realized until the mid-20th 
century. During the 1940s and 1950s, scientists at the United States Army’s 
biological warfare laboratories at Fort Detrick, Maryland, conducted extensive 
research on Botulinum Toxin as a potential biological weapon. Although the 
military applications of the toxin were never fully realized, this research paved the
way for understanding the toxin’s therapeutic potential.
In the 1960s, Dr. Alan B. Scott, an ophthalmologist, began investigating the 
potential use of Botulinum Toxin to treat strabismus (crossed eyes), a condition 
that was difficult to treat surgically. His research led to the development of a 
purified and diluted form of the toxin that could be injected into muscles to cause 
temporary paralysis. In 1989, the U.S. Food and Drug Administration (FDA) 
approved the use of Botulinum Toxin type A (marketed as Botox) for the 
treatment of strabismus and blepharospasm (uncontrolled blinking).
The cosmetic applications of Botulinum Toxin were discovered somewhat 
serendipitously. Jean Carruthers, a Canadian ophthalmologist, noticed that her 
patients who received Botox treatments for eye disorders also experienced 
improvement in facial wrinkles. This observation led to a series of studies 
conducted by Jean and her husband, Alastair Carruthers, a dermatologist, which 
eventually led to the FDA approval of Botox for cosmetic use in 2002.
Since then, the use of Botulinum Toxin in cosmetic dermatology has skyrocketed.
It is now used to treat a variety of conditions, including forehead wrinkles, crow’s 
feet, and frown lines. The toxin works by blocking the nerve signals to the 
muscles, causing them to relax and reducing the appearance of wrinkles.
The journey of Botulinum Toxin from a deadly poison to a beloved wrinkle 
reducer is a testament to the power of scientific research and innovation. As our 
understanding of this potent neurotoxin continues to grow, so too will its 
applications in cosmetic dermatology and beyond.
Different Botulinum Toxins
BOTOX Cosmetic (onabotulinumtoxinA): 
Indication
This drug is used in adults for temporary improvement in the appearance of 
moderate to severe glabellar lines (lines between the eyebrows) associated with 
corrugator and/or procerus muscle activity. It is also indicated for the treatment of
moderate to severe lateral canthal lines (crow’s feet) associated with orbicularis 
oculi activity, and moderate to severe forehead lines associated with frontalis 
muscle activity. 
Dilution
This drug is supplied in single-dose 50 Units and 100 Units per vial. It should be 
reconstituted with sterile, preservative-free 0.9% Sodium Chloride Injection USP 
to obtain a solution at a concentration of 4 Units/0.1 mL. The reconstituted 
BOTOX Cosmetic should be clear, colorless, and free of particulate matter. It 
should be administered within 24 hours after reconstitution and stored in a 
refrigerator during this time period. The vials are for single-dose only.
Administration
The drug is administered intramuscularly into five sites, two each corrugator 
muscle and one in the procerus muscle for a total dose of 20 Units. The dosage 
for simultaneous treatment with lateral canthal lines is 64 Units, comprised of 20 
Units for forehead lines, 20 Units for glabellar lines, and 24 Units for lateral 
canthal lines. The drug should be administered no closer than 1 cm above the 
central eyebrow to reduce the risk of ptosis.
Storage
The product is supplied as a vacuum-dried powder in single-dose vials of 50 or 
100 Units. Unopened vials should be stored in a refrigerator (2° to 8°C). 
Reconstituted BOTOX Cosmetic should also be stored in a refrigerator and used 
within 24 hours.
DYSPORT (abobotulinumtoxinA): 
Indication
This drug is indicated for the temporary improvement in the appearance of 
moderate to severe glabellar lines associated with procerus and corrugator 
muscle activity in adults less than 65 years of age.
Dilution
This drug is supplied as a dry powder in single-dose 300 Unit and 500 Unit vials. 
It should be reconstituted with preservative-free 0.9% Sodium Chloride Injection, 
USP using aseptic technique. The reconstituted DYSPORT should be a clear, 
colorless solution, free of particulate matter. It should be used for only one 
injection session and for only one patient. Once reconstituted, it can be stored in 
a refrigerator, protected from light for up to 24 hours until time of use.
Administration
The dose for the treatment of glabellar lines in adults is a total of 50 Units given 
intramuscularly in five equal aliquots of 10 Units each to achieve clinical effect. 
The drug should be administered no more frequently than every three months. 
To reduce the risk of ptosis, the drug should be injected at least 1 centimeter 
above the bony supraorbital ridge and no closer than 1 centimeter above the 
central eyebrow.
Storage
This is supplied as a sterile, lyophilized powder in a single-dose, glass vial. 
Unopened vials must be stored refrigerated (2°C to 8°C) and protected from light.
XEOMIN (incobotulinumtoxinA): 
Indication
It is indicated for temporary improvement in the appearance of moderate to 
severe glabellar lines with corrugator and/or procerus muscle activity.
Dilution
It should be reconstituted with only 2.5mL sterile, preservative-free 0.9% Sodium 
Chloride Injection, USP to obtain a solution at a concentration of 4 Units/0.1 mL. 
The frequency of XEOMIN treatments should be no sooner than every 12 weeks.
Administration
The drug is administered intramuscularly into five sites, two injections into medial
corrugator and lateral corrugator muscles respectively, and one injection in the 
procerus muscle for a total dose of 20 Units. To reduce the risk of ptosis, the 
drug should be injected no less than 1 centimeter above the superior orbital rim.
Storage
Supplied in single-dose vials of 50, 100, or 200 Units. Unopened vials can be 
stored at room temperature (20°C to 25°C), in a refrigerator (2°C to 8°C), or a 
freezer (-20°C to -10°C). Reconstituted XEOMIN should not be used if the 
solution appears cloudy or contains particulate matter, and any unused solution 
should be discarded after 24 hours.
JEUVEAU (prabotulinumtoxinA-xvfs):
Indication
This drug is indicated for the temporary improvement in the appearance of 
moderate to severe glabellar lines associated with corrugator and/or procerus 
muscle activity in adult patients.
Dilution
This drug is supplied in a single-dose 100 Unit vial. It should be reconstituted 
with only 2.5mL sterile, preservative-free 0.9% Sodium Chloride Injection, USP to
obtain a solution at a concentration of 4 Units/0.1 mL. The reconstituted 
JEUVEAU should be clear, colorless, and free of particulate matter. It should be 
administered within 24 hours after reconstitution and stored in a refrigerator 
during this time period. The vials are for single-dose only.
Administration
The drug is administered intramuscularly into five sites, two injections into medial
corrugator and lateral corrugator muscles respectively, and one injection in the 
procerus muscle for a total dose of 20 Units. To reduce the risk of ptosis, the 
drug should be injected no less than 1 centimeter above the superior orbital rim.
Storage
Supplied as a vacuum-dried powder in a single-dose vial of 100 Units. Unopened
vials should be stored in a refrigerator (2° to 8°C) and protected from light.
DAXXIFY (daxibotulinumtoxinA-lanm)
Indication
This drug is indicated for the temporary improvement in the appearance of 
moderate to severe glabellar lines associated with corrugator and/or procerus 
muscle activity in adult patients.
Dilution
This drug is supplied in single-dose 50 Unit and 100 Unit vials. It should be 
reconstituted with the required amount of sterile, preservative-free 0.9% Sodium 
Chloride Injection, USP to obtain a solution at a concentration of 8 Units/0.1 mL. 
The reconstituted DAXXIFY solution should be clear to slightly opalescent and 
colorless and free of particulate matter. It should be administered within 72 hours
after reconstitution and stored in a refrigerator during this time period.
Administration
The drug is administered intramuscularly into five sites, two injections into medial
corrugator and lateral corrugator muscles respectively, and one injection in the 
procerus muscle for a total dose of 40 Units. To reduce the risk of ptosis, the 
drug should be injected no less than 1 centimeter above the superior orbital rim.
Storage
Supplied as a sterile lyophilized powder in single-dose vials of 50 or 100 Units. 
Unopened vials should be stored at room temperature (20°C to 25°C) or 
refrigerated (2°C to 8°C) and protected from light.
General Contraindications
Botulinum toxin drugs are contraindicated in patients with:
Known hypersensitivity to any botulinum toxin products or to any of the 
components in the formulation. This includes specific hypersensitivity to cow’s 
milk protein, which may be present in trace amounts in some formulations.
Presence of infection at the proposed injection site(s).
These contraindications apply to all the mentioned botulinum toxin drugs: 
BOTOX Cosmetic, DYSPORT, XEOMIN, JEUVEAU, and DAXXIFY.
Warnings and Precautions
Lack of Interchangeability between Botulinum Toxin Products
The potency units of botulinum toxin products, including BOTOX Cosmetic 
(onabotulinumtoxinA), DYSPORT, XEOMIN, JEUVEAU, and DAXXIFY 
(daxibotulinumtoxinA-lanm), are specific to the preparation and assay method 
utilized. They are not interchangeable with other preparations of botulinum toxin 
products. Therefore, units of biological activity of these products cannot be 
compared to nor converted into units of any other botulinum toxin products 
assessed with any other specific assay method.
Spread of Toxin Effect: 
Postmarketing safety data from botulinum toxin products, including BOTOX 
Cosmetic, DYSPORT, XEOMIN, JEUVEAU, and DAXXIFY, suggest that 
botulinum toxin effects may, in some cases, be observed beyond the site of local 
injection. The symptoms are consistent with the mechanism of action of 
botulinum toxin and may include asthenia, generalized muscle weakness, 
diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary 
incontinence, and breathing difficulties.
These symptoms have been reported hours to weeks after injection. Swallowing 
and breathing difficulties can be life-threatening, and there have been reports of 
death related to the spread of toxin effects. Patients should be advised to seek 
immediate medical care if swallowing, speech, or respiratory difficulties occur. 
Although no serious adverse reactions of distant spread of toxin effect associated
with these products have been reported in clinical studies for their specific 
approved indications, these reactions are possible.
Serious adverse reactions with unapproved use:
Serious adverse reactions, including excessive weakness, dysphagia, and 
aspiration pneumonia, with some adverse reactions associated with fatal 
outcomes, have been reported in patients who received botulinum toxin 
injections for unapproved uses. These adverse reactions were not necessarily 
related to distant spread of toxin, but may have resulted from the administration 
of botulinum toxin products to the site of injection and/or adjacent structures. In 
several cases, patients had pre-existing dysphagia or other significant 
disabilities. There is insufficient information to identify factors associated with an 
increased risk for adverse reactions associated with the unapproved uses of 
botulinum toxin products. The safety and effectiveness of botulinum toxin for 
unapproved uses have not been established.
Hypersensitivity Reactions:
Serious and/or immediate hypersensitivity reactions have been reported for 
botulinum toxin products. These reactions include anaphylaxis, serum sickness, 
urticaria, soft tissue edema, and dyspnea. If such a reaction occurs, further 
injection of the botulinum toxin product should be discontinued and appropriate 
medical therapy immediately instituted. The use of botulinum toxin products in 
patients with a known hypersensitivity to any botulinum neurotoxin or to any of 
the components in the formulation could lead to a life-threatening allergic 
reaction.
Cardiovascular System:
There have been reports following administration of botulinum toxins of adverse 
events involving the cardiovascular system, including arrhythmia and myocardial 
infarction, some with fatal outcomes. Some of these patients had risk factors 
including pre-existing cardiovascular disease. Use caution when administering to 
patients with pre-existing cardiovascular disease.
Increased Risk with Pre-Existing Neuromuscular Disorders:
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral 
sclerosis, or neuromuscular junction disorders (e.g., myasthenia gravis or 
Lambert-Eaton syndrome) should be monitored particularly closely when given 
botulinum toxin. Patients with neuromuscular disorders may be at increased risk 
of clinically significant effects including generalized muscle weakness, diplopia, 
ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise.
Dysphagia and Breathing Difficulties:
Treatment with botulinum toxin products can result in swallowing or breathing 
difficulties. Patients with pre-existing swallowing or breathing difficulties may be 
more susceptible to these complications. In most cases, this is a consequence of
weakening of muscles in the area of injection that are involved in breathing or 
swallowing. Deaths as a complication of severe dysphagia have been reported 
after treatment with botulinum toxin. Dysphagia may persist for several months, 
and require use of a feeding tube to maintain adequate nutrition and hydration. 
Aspiration may result from severe dysphagia and is a particular risk when 
treating patients in whom swallowing or respiratory function is already 
compromised. Treatment with botulinum toxins may weaken neck muscles that 
serve as accessory muscles of ventilation. This may result in a critical loss of 
breathing capacity in patients with respiratory disorders who may have become 
dependent upon these accessory muscles. There have been postmarketing 
reports of serious breathing difficulties, including respiratory failure. Patients 
treated with botulinum toxin may require immediate medical attention should they
develop problems with swallowing, speech or respiratory disorders. These 
reactions can occur within hours to weeks after injection with botulinum toxin.
Pre-existing Conditions at the Injection Site: 
Caution should be used when botulinum toxin treatment is used in the presence 
of inflammation at the proposed injection site(s), ptosis, or when excessive 
weakness or atrophy is present in the targeted muscle(s). This also applies to 
patients who have marked facial asymmetry, excessive dermatochalasis, deep 
dermal scarring, thick sebaceous skin, or when subjects do not respond to 20 
Units of botulinum toxin (e.g., the inability to substantially lessen glabellar lines 
even by physically spreading them apart). Use caution when administering to 
patients with surgical alterations to the facial anatomy. Do not exceed the 
recommended dosage and frequency of administration.
Corneal Exposure and Ulceration: 
This may require protective drops, ointment, or closure of the eye by patching or 
other means. Because of its anticholinergic effects, botulinum toxin should be 
used with caution in patients at risk of developing narrow angle glaucoma. To 
prevent ectropion, botulinum toxin products should not be injected into the medial
lower eyelid area. Ecchymosis easily occurs in the soft tissues of the eyelid. 
Immediate gentle pressure at the injection site can limit that risk.
Ophthalmic Adverse Reactions: 
Dry Eye: 
Dry eye has been reported with the use of botulinum toxin products in the 
treatment of glabellar lines. Reduced tear production, reduced blinking, and 
corneal disorders may occur with use of botulinum toxins. If symptoms of dry eye
(e.g., eye irritation, photophobia, or visual changes) persist, consider referring the
patient to an ophthalmologist.
Spatial Disorientation and Double Vision Treated for Strabismus: 
Inducing paralysis in one or more extraocular muscles may produce spatial 
disorientation, or double vision.. Covering the affected eye may alleviate these 
symptoms.
Human Albumin and Transmission of Viral Diseases: 
The product contains albumin, a derivative of human blood. Based on effective 
donor screening and product manufacturing processes, it carries an extremely 
remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob 
disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob 
disease (CJD), but if that risk actually exists, the risk of transmission would also 
be considered extremely remote. No cases of transmission of viral diseases, CJD
or vCJD have ever been identified for licensed albumin or albumin contained in 
other licensed products.
Facial Anatomy in the Treatment of Glabellar Lines: 
Caution should be exercised when administering botulinum toxin to patients with 
surgical alterations to the facial anatomy, excessive weakness or atrophy in the 
target muscle(s), marked facial asymmetry, inflammation at the injection site(s), 
ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin, 
or the inability to substantially lessen glabellar lines by physically spreading them
apart. Do not exceed the recommended dosage and frequency of administration. 
In clinical trials, subjects who received a higher dose had an increased incidence 
of eyelid ptosis.
Intradermal Immune Reaction: 
The possibility of an immune reaction when injected intradermally is unknown. 
The safety of botulinum toxin for the treatment of hyperhidrosis has not been 
established. It is approved only for intramuscular injection.
Side Effects/ Adverse 
Reactions
Here is the list of major side effects taken from the Xeomin, botulinum toxin. Most
botulinum toxin share similar side effect / adverse event profile. Please check 
your package insert for a detailed list.

Immunogenicity
As with all therapeutic proteins, there is a potential for immunogenicity. The 
detection of antibody formation is highly dependent on the sensitivity and 
specificity of the assay. Additionally, the observed incidence of antibody 
(including neutralizing antibody) positivity in an assay may be influenced by 
several factors including assay methodology, sample handling, timing of sample 
collection, medications, and underlying disease. For these reasons, comparison 
of the incidence of antibodies to botulinum toxin in different studies or to other 
products may be misleading.
Treatment with botulinum toxins may result in the formation of neutralizing 
antibodies that may reduce the effectiveness of subsequent treatments by 
inactivating the biological activity of the toxin. The critical factors for neutralizing 
antibody formation have not been well characterized. The results from some 
studies suggest that botulinum toxin injections at more frequent intervals or at 
higher doses may lead to a greater incidence of antibody formation. The potential
for antibody formation may be minimized by injecting with the lowest effective 
dose given at the longest feasible intervals between injections.
Post Marketing Experience
Because these reactions are reported voluntarily from a population of uncertain 
size, it is not always possible to reliably estimate their frequency or establish a 
causal relationship to drug exposure. The following adverse reactions have been 
identified during post-approval use of botulinum toxin products:
Death, sometimes associated with dysphagia, pneumonia, and/or other 
significant debility or anaphylaxis.
Adverse events involving the cardiovascular system, including arrhythmia and 
myocardial infarction, some with fatal outcomes. Some of these patients had risk 
factors including cardiovascular disease.
New onset or recurrent seizures, typically in patients who are predisposed to 
experiencing these events.
Ear and labyrinth disorders: Hypoacusis; tinnitus; vertigo.
Eye disorders: Diplopia; dry eye; lagophthalmos; strabismus; visual disturbances;
vision blurred.
Gastrointestinal disorder: Abdominal pain; diarrhea; dry mouth; nausea; vomiting.
General disorders and administration site conditions: Denervation; malaise; 
pyrexia.
Metabolism and nutrition disorders: Anorexia.
Musculoskeletal and connective tissue disorders: Localized muscle 
twitching/involuntary muscle contractions; muscle atrophy; myalgia.
Nervous system disorders: Brachial plexopathy; dysarthria; facial palsy; 
hypoaesthesia; localized numbness; myasthenia gravis; paresthesia; peripheral 
neuropathy; radiculopathy; syncope.
Respiratory, thoracic and mediastinal disorders: Aspiration pneumonia; dyspnea; 
respiratory depression and/or respiratory failure.
Skin and subcutaneous tissue disorders: Alopecia, including madarosis; 
hyperhidrosis; pruritus; skin rash (including erythema multiforme, dermatitis 
psoriasiform, and psoriasiform eruption).
Vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial
paresis, hypoesthesia, erythema, dry eye, and excessive granulation tissue.
Hypersensitivity reactions including anaphylaxis.
Eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site 
pain, injection site reaction, allergic dermatitis, localized allergic reactions like 
swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, 
muscle spasm, dysarthria, myalgia and hypersensitivity.
Drug Interactions
Aminoglycosides and Other Agents Interfering with Neuromuscular 
Transmission: Co-administration of botulinum toxin and aminoglycosides or other
agents interfering with neuromuscular transmission (e.g., curare-like compounds 
or tubocurarine-type muscle relaxants) should only be performed with caution as 
the effect of the toxin may be potentiated. If co-administered, the patient should 
be observed closely.
Anticholinergic Drugs: Use of anticholinergic drugs after administration of 
botulinum toxin may potentiate systemic anticholinergic effects such as blurred 
vision.
Other Botulinum Neurotoxin Products: The effect of administering different 
botulinum neurotoxin products at the same time or within several months of each 
other is unknown. Excessive neuromuscular weakness may be exacerbated by 
administration of another botulinum toxin prior to the resolution of the effects of a 
previously administered botulinum toxin.
Muscle Relaxants: Excessive weakness may also be exaggerated by 
administration of a muscle relaxant before or after administration of botulinum 
toxin.
Specific Populations
Pregnancy: There are no adequate data from postmarketing surveillance on the 
developmental risk associated with the use of botulinum toxin in pregnant 
women. In animal studies, administrations of botulinum toxin during pregnancy 
resulted in adverse effects on fetal growth (decreased fetal body weight and 
skeletal ossification) at clinically relevant doses, which were associated with 
maternal toxicity. 
Lactation: There are no data on the presence of botulinum toxin in human or 
animal milk, the effects on the breastfed child, or the effects on milk production. 
The developmental and health benefits of breastfeeding should be considered 
along with the mother’s clinical need for botulinum toxin and any potential 
adverse effects on the breastfed infant from botulinum toxin or from the 
underlying maternal conditions.
Pediatric Use: Safety and effectiveness in patients below the age of 18 years 
have not been established for botulinum toxin.
Geriatric Use: In clinical studies of botulinum toxin, the responder rates appeared
to be higher for subjects younger than age 65 than for subjects 65 years or older.
However, no overall differences in safety or effectiveness were observed 
between older and younger patients. Other clinical studies have not identified 
differences in responses between older and younger patients, but increased 
sensitivity in older patients cannot be ruled out.
Females and Males of Reproductive Potential: In rats, botulinum toxin produced 
adverse effects on mating behavior and fertility.
Ethnic Groups: Exploratory analyses in trials for glabellar lines in African-
American subjects with Fitzpatrick skin types IV, V, or VI and in Hispanic subjects
suggested that response rates at Day 30 were comparable to and no worse than 
the overall population.
Overdose
Excessive doses of botulinum toxin, whether it’s BOTOX Cosmetic 
(onabotulinumtoxinA), DYSPORT, XEOMIN, JEUVEAU 
(prabotulinumtoxinAxvfs), or DAXXIFY, may be expected to produce 
neuromuscular weakness with a variety of symptoms. Symptoms of overdose are
likely not to be present immediately following injection.
Should accidental injection or oral ingestion occur, or overdose be suspected, 
these patients should be considered for further medical evaluation and 
appropriate medical therapy immediately instituted, which may include 
hospitalization. The person should be medically supervised for several weeks for 
signs and symptoms of systemic muscular weakness which could be local, or 
distant from the site of injection.
In the event of overdose, antitoxin raised against botulinum toxin is available 
from the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. 
However, the antitoxin will not reverse any botulinum toxin-induced effects 
already apparent by the time of antitoxin administration.
In the event of suspected or actual cases of botulinum toxin poisoning, please 
contact your local or state Health Department to process a request for antitoxin 
through the CDC. 
Clinical Pharmacology
Mechanism of Action 
The mechanism of action of botulinum toxin involves several steps:
1. Binding: The botulinum toxin binds to specific surface receptors on nerve 
endings. This binding is facilitated by the heavy chain of the toxin molecule.
2. Internalization: Once bound, the toxin is internalized into the nerve terminal 
through a process known as receptor-mediated endocytosis.
3. Inhibition of Acetylcholine Release: Inside the nerve terminal, the toxin cleaves
a pre-synaptic protein called SNAP-25. This protein is integral to the successful 
docking and release of acetylcholine, a neurotransmitter responsible for muscle 
contraction, from vesicles situated within nerve endings. The cleavage of SNAP-
25 inhibits the release of acetylcholine, leading to a localized reduction in muscle 
activity.
4. Muscle Response: The affected muscle undergoes partial chemical 
denervation, which may lead to muscle atrophy. These changes contribute to the 
muscle’s reduced activity and the wrinkle smoothing.
The effects of botulinum toxin are not permanent. Over time, the muscle begins 
to regain its strength through a process known as reinnervation. This occurs as 
the neuromuscular junction recovers from SNAP-25 cleavage and new nerve 
endings are formed. The parent nerve terminal regains function, and the 
collateral terminals, which had sprouted during the period of denervation, retract. 
This gradual recovery of muscle function ensures the safety of botulinum toxin 
use in cosmetic medicine, as the effects can be reversed over time.
Pharmacodynamics: 
No formal pharmacodynamic studies have been conducted with these toxins. 
The primary pharmacodynamic effect is due to chemical denervation of the 
treated muscle resulting in a measurable decrease of the compound muscle 
action potential, causing a localized reduction in muscle activity. The return of 
increased muscle tone following injection typically occurs within 3 to 4 months.
Pharmacokinetics: 
Using currently available analytical technology, it is not possible to detect these 
toxins in the peripheral blood following intramuscular injection at the 
recommended doses.
Carcinogenesis, Mutagenesis, Impairment of Fertility: 
Long term studies in animals have not been performed to evaluate carcinogenic 
potential of these toxins. They were negative in a battery of in vitro and in vivo 
genetic toxicologic assays. In fertility studies, reduced fertility was observed in 
males and females at high doses. 
Patient Consultation
The patient consultation is a critical component of a successful botulinum toxin 
treatment. It provides an opportunity to understand the patient’s concerns, set 
realistic expectations, and plan the treatment accordingly. 
Initial Consultation
1. Patient History: Begin with a comprehensive history, including medical 
conditions, previous cosmetic procedures, allergies, and medications. This 
information is crucial to assess the suitability of botulinum toxin treatment and to 
anticipate potential complications.
2. Informed Consent: Explain the procedure, potential risks, benefits, and 
alternatives to the patient. Ensure they understand the information and have the 
opportunity to ask questions. Obtain written consent before proceeding with the 
treatment.
3. Photographic Documentation: Take standardized ‘before’ photographs from 
multiple angles. These photos serve as a reference for treatment planning and to
evaluate the treatment outcome.
Patient Examination
1. Patient Concerns: Provide a mirror and ask the patient to point out the areas of
concern. Ask them to animate their face to illustrate their concerns better. This 
step helps to understand the patient’s perception of their appearance and their 
aesthetic goals.
2. Facial Analysis: Conduct a thorough examination of the face, noting 
asymmetries, skin quality, muscle strength, and the depth and location of 
wrinkles. Point out any asymmetries to the patient and document them in the 
medical record.
3. Glogau Wrinkle Scale: Use the Glogau Wrinkle Scale to assess the severity of 
wrinkles. This scale categorizes wrinkles into four types, each associated with a 
specific age group and recommended treatment:
    – Type 1: ‘Early Wrinkles’ (20s to 30s) – botulinum toxin is typically sufficient.
    – Type 2: ‘Wrinkles in Motion’ (30s to 40s) – botulinum toxin and possibly 
dermal fillers may be needed.
    – Type 3: ‘Wrinkles at Rest’ (50s & older) – botulinum toxin and dermal fillers 
will likely be required.
    – Type 4: ‘Only Wrinkles’ (60s or 70s) – botulinum toxin and dermal fillers may 
not be enough; consider facelift or laser resurfacing.
4. Glabellar Spread Test: This test helps determine if botulinum toxin alone will 
soften a patient’s frown lines. Spread the glabellar wrinkles apart with your thumb
and index fingers. Patients with thick skin and deep dermal folds who do not 
improve with manual spreading may need dermal filler injections alongside 
botulinum toxin.
Setting Expectations
1. Realistic Expectations: Discuss the expected outcomes and limitations of 
botulinum toxin treatment. Emphasize that the typical goal is to enhance their 
natural beauty and not to completely change their appearance.
2. Patient Education: Educate the patient about the procedure, post-treatment 
care, and the need for follow-up sessions. Explain that the effects of botulinum 
toxin are temporary and regular treatments are necessary to maintain the results.
3. Treatment Plan: Based on the patient’s concerns, facial analysis, and wrinkle 
assessment, develop a personalized treatment plan. Discuss the plan with the 
patient, including the areas to be treated, the type of botulinum toxin to be used, 
and the estimated cost.
The patient consultation is not just about gathering information but also about 
building a therapeutic relationship with the patient. A well-conducted consultation 
can lead to high patient satisfaction and a successful treatment outcome.
Counseling
Patients should be informed that injections of botulinum toxins, such as BOTOX 
Cosmetic, DYSPORT, XEOMIN, JEUVEAU, and DAXXIFY, may lead to potential
swallowing, speaking, or breathing difficulties, or other unusual symptoms. If 
such symptoms develop or existing symptoms worsen, patients or caregivers 
should seek immediate medical care.
Patients should also be aware that these injections may cause eye dryness, and 
they should report any symptoms of eye dryness, such as eye pain, eye irritation,
photosensitivity, or changes in vision, to their doctor.
In addition, patients should be advised to avoid driving a car or engaging in other 
potentially hazardous activities if they experience loss of strength, muscle 
weakness, blurred vision, or drooping eyelids.
It’s important to note that these are general guidelines and the specific details 
may vary between the different toxins. Always refer to the specific patient 
counseling information for each toxin for the most accurate information.
Injecting the Glabella/Procerus
and Corrugator Muscle
The glabellar region, often referred to as the ‘frown lines,’ is a common area for 
botulinum toxin injections. The primary muscles involved in this region are the 
procerus and corrugator muscles.
Muscles Involved and Action
1. Procerus: This muscle originates from the nasal bone and inserts into the 
medial forehead and skin of the brow. Its action is to draw the medial brow 
inferiorly, contributing to the horizontal lines seen on the forehead.
2. Corrugator: The corrugator muscle originates from the medial superciliary arch
and inserts into the skin of the medial forehead. It draws the brow medially and 
inferiorly, leading to the formation of vertical lines between the eyebrows.
Landmarks
Identifying the correct landmarks is crucial for successful injections. Here are the 
key landmarks for glabellar injections:
1. Medial Corrugator: The injection should be 1 cm above the bony orbital rim 
and vertical to the medial canthus.
2. Lateral Corrugator: The injection should be 1 cm above the bony orbital rim 
and medial to the vertical mid-pupillary line.
3. Procerus: The injection should be just above the crossing point of the ‘X’ 
formed by drawing a line from the medial eyebrow contralateral to the medial 
canthus.
Injection Technique
All injections for the glabella are intramuscular and perpendicular to the skin. The
needle should be above the periosteum. It’s important to note that the frontalis 
muscle overlaps the corrugator superficially, so a superficial injection may cause 
paralysis of the inferior edges of the frontalis muscle. Therefore, corrugator 
injections should be deep intramuscular injections.
Previously, the recommendation was to inject until hitting the periosteum, then 
pull back several millimeters before injecting the botulinum toxin. However, this 
technique has been modified as it was found to increase the incidence of 
headaches in patients and dull the needle for subsequent injections.
The standard FDA-approved dose for glabellar lines, as per the BOTOX® 
Cosmetic package insert, is 20 units. However, men may require an additional 1-
2 units per injection site due to typically larger muscle mass.
Complications and Solutions
The complication rate for glabellar injections is 1-3%. Potential complications 
include:
1. Lid Ptosis: This can occur if the injection is too close to the orbital rim, as 
diffusion of the botulinum toxin may affect the levator palpebrae superioris 
muscle.
2. Brow Ptosis: This can occur if the injection is placed too superficially (affecting 
the frontalis muscle) or too lateral to the mid-pupillary line. 
Complications can appear as soon as 48 hours or as late as 7 days post-injection
and may persist for 4-8 weeks. Solutions include:
1. Lid Ptosis: Apraclonidine 0.5% drop can be used, one drop to the affected eye 
three times a day. This stimulates Mueller’s muscles to minimize the ptosis. 
Oxymetazoline 0.1%, which has the FDA approval for lid ptosis, can also be 
used. 
2. Brow Ptosis: A brow lift injection technique can be attempted. However, 
typically, time is required for frontalis movement to reappear to lift the brow up 
once again.
Injecting the Brow for a Brow 
Lift
Injections above near the brows that paralyzes the depressor muscles and create
a “brow lift” like effect. 
Muscles Involved and Action
The primary muscles involved in a brow lift procedure using botulinum toxin are 
the Procerus and the Orbicularis Oculi.
Procerus
The Procerus muscle originates from the nasal bone and inserts into the medial 
forehead and skin of the brow. Its primary action is to draw the medial brow 
inferiorly, contributing to the formation of horizontal wrinkles on the bridge of the 
nose.
Orbicularis Oculi
The Orbicularis Oculi is a circumferential muscle group that functions like a 
sphincter or a purse string. It originates from the medial palpebral ligament and 
inserts into the lateral palpebral raphe, corrugator, frontalis, and depressor 
supercilii. Its action pulls the skin of the forehead, temple, and cheek toward the 
medial angle of the orbit, and it is also responsible for closing the eyelids.
Landmarks
The key landmarks for a brow lift procedure are the crossing point of the X 
formed by drawing a line from the medial eyebrow contralateral to the medial 
canthus for the Procerus, and the superolateral portion of the Orbicularis Oculi as
it curves infralaterally lateral to the temporal fusion line for the Orbicularis Oculi.
Injection Technique
Procerus
The Procerus should receive a deep intramuscular injection, just above the 
periosteum. Inject 4 units of botulinum toxin to the Procerus just above the 
crossing point of the X formed by drawing a line from the medial eyebrow 
contralateral to the medial canthus.
Orbicularis Oculi
For the Orbicularis Oculi, inject 3 units subcutaneously to the superolateral 
portion of the muscle as it curves infralaterally lateral to the temporal fusion line. 
Ensure that the movement of the lateral portions of the frontalis muscles is not 
felt in this superolateral injection site to avoid injecting the frontalis and creating 
brow ptosis. The injection should be placed 1 cm outside of the bony orbital rim.
Complications and Solutions
The primary complication of a brow lift procedure is brow ptosis, or drooping of 
the brow. This can be minimized by injecting superior and lateral to the orbital 
rim. If brow ptosis does occur, it will naturally resolve as the action of the 
botulinum toxin diminishes over time.
Additional Pearls
– Precise injection location and depth are crucial for achieving aesthetically 
pleasing brow outcomes and greater duration of efficacy. 
– Avoiding the frontalis muscle during injection is key to prevent brow ptosis.
– Always consider individual patient anatomy when planning and executing the 
procedure.
Injecting the Horizontal 
Forehead Lines or Frontalis 
Muscle
The primary indication for injecting the frontalis muscle is to reduce the 
appearance of horizontal forehead lines. These lines are a result of the repetitive 
contraction of the frontalis muscle, which lifts the eyebrows and furrows the 
forehead.
Muscles Involved and Action
The frontalis muscle is a broad muscle that varies in size and shape among 
individuals. Some may have a narrow or broad frontalis, while others may have a
tall or short frontalis. The shape can also vary, being either V-shaped or 
rectangle-shaped. It is important to palpate the muscle before injecting to 
understand its size and shape.
The frontalis muscle originates from the galea aponeurosis and inserts into the 
muscles of the glabellar complex. The action of the frontalis muscle is to lift the 
eyebrows superiorly and depress the scalp inferiorly. The fibers of the frontalis 
muscles are oriented vertically, while the visible wrinkles formed by the 
contraction of the frontalis muscle are horizontal.
Landmark
The frontalis muscle is located on the forehead and is easily palpable. The lower 
2-3 cm of the frontalis muscle is used to elevate the eyebrow and injection here 
should be avoided. The medial portions of the frontalis muscle fibers may be 
more fibrous or absent and may need less injection. A key point about the 
frontalis is to avoid injecting near the lowest horizontal wrinkle or at least 2-3 cm 
above the brow.
Injection Technique
The injections are subcutaneous and are typically placed roughly 2 cm apart. 
Typically, 2 units of botulinum toxin are injected per site. Men may require 1-2 
additional units per injection site due to typically having a larger muscle mass.
Complications and Solutions
The most common complications associated with frontalis muscle injections 
include brow ptosis and Spock brow.
Brow ptosis: This can occur when the frontalis is treated without paralyzing the 
active brow depressor muscles (procerus and corrugator). Ideally, glabella 
muscles should be injected simultaneously. Another cause of brow ptosis is 
when the frontalis muscle, which is hyperfunctional, supports a normally ptotic 
upper eyelid. To avoid complete paralysis of the frontalis muscle, it is 
recommended to avoid injecting near the first horizontal line or at least 2-3 cm 
above the brow.
Spock brow: This can occur when the lateral fibers of the frontalis muscles have 
not been paralyzed. The solution is to inject 1-2 units where you feel the 
untreated lateral fibers of the frontalis muscle when you ask your patients to lift 
their eyebrows. It should be noted that some patients may actually prefer the 
“Spock brow” look.
Additional Pearls
1. Always palpate the frontalis muscle before injecting to understand its size and 
shape. This will help in determining the amount of botulinum toxin needed and 
the best injection sites.
2. Always avoid injecting near the lowest horizontal wrinkle line or at least 2-3 cm
above the brow to prevent brow ptosis.
3. When treating the frontalis muscle, consider also treating the glabella muscles 
to prevent brow ptosis.
4. Be aware of the possibility of a Spock brow and know how to correct it if it 
occurs.
Injecting the Crow’s Feet or 
Orbicularis Oculi
Muscles Involved and Action
The orbicularis oculi is a single, circumferential muscle group that functions like a
sphincter or purse string. The muscle originates from the medial palpebral 
ligament and inserts into the lateral palpebral raphe, corrugator, frontalis, and 
depressor supercilii. Its primary action involves pulling the skin of the forehead, 
temple, and cheek toward the medial angle of the orbit, resulting in the closure of
the eyelids.
Landmark
The landmark for the injection is 1 cm outside of the bony orbital rim or 2 cm 
outside of the lateral cantus. Placing the non-injecting index finger into the bony 
rim can help identify this landmark. The injection site should not be below the 
zygomatic arch to avoid diffusion into the zygomatic muscles, which can affect 
the smile.
Injection Technique
The injection technique for the orbicularis oculi involves subcutaneous injections, 
typically 1 cm apart in a slightly curving arch. Each injection typically contains 3 
units of botulinum toxin. Men may require an additional 1 unit per injection site 
due to their typically thicker skin and stronger muscle mass.
Complications and Solutions
The most common complications include asymmetrical smile or diplopia due to 
migration of the toxin. To avoid this, it is crucial to inject 1 cm outside of the bony 
orbital rim. Excessive wrinkles underneath the lower lid may become 
accentuated if medial portions of the Orbicularis Oculi are left unopposed. This 
may require injection into the lower/medial parts of the Orbicularis Oculi or the 
Nasalis muscle. 
Injecting the Lower Eyelid
Botulinum toxin injections in the lower eyelid are primarily indicated for the 
treatment of wrinkles below the lower eyelid and narrow palpebral aperture.
Muscles Involved
The primary muscle involved in this procedure is the Orbicularis Oculi. This 
muscle is a circumferential muscle group that functions like a sphincter or purse 
string. It originates from the medial palpebral ligament and inserts into the lateral 
palpebral raphe, corrugator, frontalis, and depressor supercili. Its action pulls the 
skin of the forehead, temple, and cheek toward the medial angle of the orbit, and 
it is responsible for closing the eyelids.
Injection Technique
The injection technique for the lower eyelid involves a subcutaneous injection of 
botulinum toxin. The standard dose is 1 unit, injected 0.5 cm below the lower lid 
margin in line with the midpupillary line. Some individuals may require an 
additional unit for optimal results. It is important to avoid injections medial to the 
pupil to minimize the risk of complications.
Complications
The most common complication of lower eyelid injections is bruising, as this is a 
vascular area. Other potential complications include ectropion, where the lower 
lid turns outwards, and epiphora, which is excessive tear production. These 
complications are extremely rare but can occur.
To minimize the risk of ectropion, it is crucial to select patients appropriately. 
Patients with a history of lower lid ablative resurfacing or blepharoplasty may be 
contraindicated. Even in the absence of these contraindications, it is 
recommended to perform a snap test before proceeding with the injection. This 
test involves pulling the lower eyelid downward; a return to its normal position in 
less than 1 second is considered normal. Any patient with a time greater than 1 
second should not be treated.
Injecting the Nasalis/Bunny 
Nose Lines
Muscles Involved and Action
The primary muscles involved in the formation of bunny nose lines are the 
Nasalis and Procerus muscles. Treatment of both the Procerus and Nasalis is 
necessary to diminish the horizontal and vertical lines on the bridge of the nose.
The Nasalis muscle, originating in the maxilla, is a complex structure that inserts 
into the aponeurosis of the Procerus and continues over the bridge of the nose 
onto the other side. Its primary function is to draw the skin of the nose superiorly 
and medially. Procerus muscle, which originates from the nasal bone, inserts into
the medial forehead and skin of the brow. Its primary function is to draw the 
medial brow inferiorly.
Landmarks
When it comes to injecting these muscles, accurate identification of the 
landmarks is crucial. For the Nasalis, the injection site is anterior and medial to 
the nasofacial groove on the lateral nose. For the Procerus, the injection is 
performed just above the crossing point of the X formed by drawing a line from 
the medial eyebrow contralateral to the medial canthus.
Injection technique 
The Procerus requires a deep intramuscular injection, above the periosteum, with
an injection of 4 units at the identified landmark. The Nasalis, on the other hand, 
requires a subcutaneous injection, with 2 units injected at the landmark.
Complications
One potential complication is upper lip ptosis due to diffusion into muscles lateral 
to the Nasalis muscle. To avoid this, ensure the injection is performed medial and
anterior to the nasofacial groove, thus avoiding the levator muscles of the lip.
Injecting the Lip for a Lip Flip
Muscles Involved and Action
The primary muscle involved in the lip flip procedure is the orbicularis oris 
muscle. This muscle encircles the mouth and is responsible for various lip 
movements, including closing the lips, puckering, and other complex movements 
necessary for speech and facial expression. 
When botulinum toxin is injected into the orbicularis oris muscle, it causes a 
temporary paralysis of the muscle. This results in a slight eversion or ‘flip’ of the 
lip, giving the appearance of a fuller and more pronounced upper lip.
Landmark
The landmark for the lip flip procedure is the vermilion border of the upper lip. 
The vermilion border is the line where the pink-red lip tissue meets the 
surrounding skin. The injections are typically placed along this border at several 
points across the upper lip.
Injection Technique
The injection technique for a lip flip involves the careful placement of 1-2 units 
into the orbicularis oris muscle. The injections are typically administered using a 
fine needle, and the procedure is usually performed without anesthesia as it 
causes minimal discomfort. 
The injections are placed along the vermilion border of the upper lip, typically at 
2-3 points on each side of the midline. The exact number and placement of 
injections can vary depending on the individual patient’s anatomy and desired 
results.
Complications and Solutions
Complications from a lip flip procedure are generally rare and mild, but can 
include:
– Asymmetry: This can occur if the botulinum toxin is not evenly distributed on 
both sides of the lip. It can be corrected in a follow-up appointment with 
additional injections to balance the effect.
– Difficulty with lip movements: Over-paralysis of the orbicularis oris muscle can 
lead to difficulty with certain lip movements, such as puckering or drinking from a 
straw. This is usually temporary and resolves as the effect wears off.
– Bruising or swelling at the injection site: This is a common side effect of any 
injection and usually resolves on its own within a few days.
Additional Pearls
– The effect of the lip flip procedure is temporary, with muscle function typically 
beginning to return approximately 1 to 2 months after injection due to the low 
dosage.
– The lip flip procedure can be a good alternative for patients who want a more 
pronounced upper lip but do not want or are not ready for more invasive 
procedures such as fillers or surgery.
– It’s important to have a thorough understanding of the patient’s anatomy and 
desired outcome to achieve the best results with a lip flip procedure. 
– Patient education is key. Make sure patients understand that the results are 
subtle and that this procedure is different from a dermal filler injection.
Injecting the Orbicularis Oris / 
Smoker’s Lip Lines
Muscles Involved and Action
The primary muscle involved in this procedure is the Orbicularis Oris. This 
muscle originates from the buccinator and fibers at the angle of the mouth, and 
inserts symmetrically at the vermillion border. The primary action of the 
Orbicularis Oris is to close the lips, which is crucial for functions such as 
speaking, eating, and expressing emotions.
Landmark
The Orbicularis Oris is a complex muscle that encircles the mouth. It is located 
directly beneath the skin and is easily palpable. The vermillion border of the lips 
serves as a key landmark for this muscle. The muscle extends from the corners 
of the mouth and wraps around the lips, meeting at the midline.
Injection Technique
The injection technique for the Orbicularis Oris involves subcutaneous 
symmetrical injections less than 3 mm above and below the vermillion border. 
Each injection should contain 1-2 units of botulinum toxin. It is important to avoid 
injecting more than 2 units in each lip quadrant to prevent overcorrection and 
potential complications. 
The mid upper lip and the corners of the mouth should be avoided during the 
injection process. The mid upper lip is a sensitive area, and injecting it could lead
to flattening of the lip. The corners of the mouth are also crucial for facial 
expressions, and injecting them could lead to an asymmetrical smile or other 
complications.
Complications and Solutions
Potential complications of botulinum toxin injections in the Orbicularis Oris 
include an asymmetrical smile, difficulty with speech, and drooling. These 
complications can be mitigated by using a low dose of botulinum toxin and 
ensuring symmetrical injections. 
It is also recommended to avoid injecting individuals who rely heavily on their 
facial expressions for their profession, such as singers, orators, and musicians. 
These individuals may experience a significant impact on their ability to perform 
their work if any complications arise.
If a patient has a history of cold sores, it is recommended to include pretreatment
with Valtrex®. The patient should take 2 grams at the time of treatment and 2 
grams 12 hours later to prevent a herpes outbreak.
Additional Pearls
Patient Selection: It is crucial to select patients carefully for this procedure. 
Patients deep peri-oral grooves may benefit from laser resurfacing, 
microneedling or dermal filler injection.
Dysport: Introduction and 
Differences from Botox
Dysport requires an explanation, because the units are different from other 
botulinum toxins. All package inserts state that units are not interchangeable with
other preparations of botulinum toxin products. However, most commercially 
available botulinum toxins use 20 units for the glabellar line. Except for Dysport. 
Units are a measure of the biological activity of a botulinum toxin which cannot 
be compared to nor converted into units of any other botulinum toxin products 
assessed with any other specific assay method. 
Reconstitution
Dysport is supplied as a single-use vial with 300 Units per vial. Each 300 Unit vial
of Dysport is to be reconstituted with 2.5 mL of 0.9% sterile, preservative-free 
saline prior to injection. The concentration of the resulting solution will be 10 
Units per 0.08 mL. Each 300 Unit vial of Dysport may also be reconstituted with 
1.5 mL 0.9% sterile, preservative-free saline for a solution of 10 Units per 0.05 
mL to be delivered. Just as a provider can dilute Botox Cosmetic with Preserved 
(Bacteriostatic) 0.9% Sodium Chloride, Dysport may also be diluted with the 
same to increase its half-life.
Unit Conversion from Botox Cosmetic to Dysport
The striking difference between Dysport and Botox Cosmetic is the amount of 
units injected. Botox Cosmetic requires 20 units at 4 units per injection site in 
treating the glabellar area, whereas Dysport requires 50 units at 10 units per 
injection site in treating the glabellar area. This constitutes a 1:2.5 concentration 
ratio. Many other users have contended that the actual ratio should be 1:3 or 1:4.
These concentrations ultimately increase the amount of Dysport being injected. 
We recommend that you start with a 1:2.5 ratio conversion from the Botox 
Cosmetic unit injection recommendations offered at this course until you feel 
comfortable with the use of Dysport.
Comparative Studies
Studies have shown that Dysport will start working faster than Botox Cosmetic, 
last longer than Botox Cosmetic, and have a lower diffusion rate than Botox 
Cosmetic due to its high concentration. However, it’s important to note that 
individual patient results may vary, and it’s crucial to tailor the treatment plan to 
the patient’s unique needs and desired outcomes.
In conclusion, Dysport provides an effective alternative to Botox Cosmetic, with 
its own unique properties and considerations. As with any treatment, 
understanding the product and its appropriate use is key to achieving optimal 
results. 
Treatment Failure in Botulinum
Toxin Cosmetic Injection
One of the most significant challenges is treatment failure, which can be 
classified into primary and secondary nonresponse.
Primary Nonresponders:
Primary nonresponders are individuals who do not respond to their first BTX 
Cosmetic treatment. This lack of response can be attributed to several factors:
1. Static Wrinkles: The most common reason for primary nonresponse is the 
presence of static wrinkles, which are not dynamic in origin. These wrinkles are 
usually due to photodamage or age-related changes and require the injection of 
a filler material. A positive spread test often indicates this.
2. Inadequate Injection Amount: Another common cause of primary nonresponse
is an inadequate amount of BTX injected. This could be due to the patient having
strong muscles or the injection missing the targeted muscle.
3. Denatured Toxin: If the BTX has denatured, it will not produce the desired 
effect. In such cases, contact your representative for a new vial.
Secondary Nonresponders:
Secondary nonresponders are patients who initially respond to BTX Cosmetic but
lose the response on subsequent injections. The reasons for this can be:
1. Neutralizing Antibodies: Some patients may develop neutralizing antibodies to 
BTX. This is a rare side effect, but it has been observed in some patients. In such
cases, using a different Botulinum Toxin may yield better results.
2. Inadequate Injection Amount: Similar to primary nonresponse, secondary 
nonresponse can also be due to an inadequate amount of BTX injected. This 
could be due to the patient having strong muscles or the injection missing the 
targeted muscle.
Botulinum Toxin 
Complications and Treatments 
for Complications
Localized Complications
Localized complications are those that occur in the immediate area of the 
injection. These can include:
– Bruising and Bleeding: This is a common complication that can occur due to 
the puncture of blood vessels during the injection process. It is usually minor and 
resolves on its own. Applying a cold compress to the area immediately after the 
injection can help reduce bruising and swelling. Over-the-counter pain relievers 
can also be used to manage any discomfort.
– Pain and Swelling: Some patients may experience pain and swelling at the 
injection site. This is typically transient and can be managed with over-the-
counter pain relievers and cold compresses. 
– Infection: Although rare, infections can occur if the injection site is not properly 
cleaned before the procedure. If an infection is suspected, it should be treated 
promptly with antibiotics. 
Systemic Complications
Systemic complications are those that affect the entire body or multiple body 
systems. These can include:
– Botulism: This is a rare but serious complication that can occur if the toxin 
spreads beyond the injection site. Symptoms can include muscle weakness, 
difficulty swallowing, and respiratory problems. If suspected, immediate medical 
attention is required. If botulism is suspected, the patient should be hospitalized 
immediately. Antitoxin therapy should be initiated as soon as possible to 
neutralize the toxin.
– Allergic Reactions: Some patients may have an allergic reaction to the BTX. 
Symptoms can include hives, difficulty breathing, and swelling of the face, lips, 
tongue, or throat. If an allergic reaction occurs, the patient should be treated with 
epinephrine and antihistamines. In severe cases, hospitalization may be 
necessary.
Managing Lid Ptosis Complication and Treatment
Lid ptosis, or drooping of the upper eyelid, is a potential complication of 
botulinum toxin injections. It can occur when the toxin diffuses into the levator 
palpebrae superioris muscle, which is responsible for lifting the eyelid. This can 
lead to an undesirable aesthetic outcome and, in severe cases, can interfere with
vision. 
The management of lid ptosis following botulinum toxin injection involves both 
preventive and corrective measures.
Preventive Measures
1. Accurate Injection Technique: The most effective way to prevent lid ptosis is to
ensure accurate injection technique. This includes proper identification of the 
injection site, avoiding the levator palpebrae superioris muscle, and injecting the 
toxin at a safe distance from the eyelid.
2. Patient Positioning: The patient should be in an upright position during the 
injection and for 3-4 hours post-injection. This helps to minimize the diffusion of 
the toxin.
3. Patient Instructions: Patients should be instructed to avoid rubbing or 
massaging the injection area for at least 24 hours post-injection to prevent the 
spread of the toxin.
Corrective Measures
1. Alpha-adrenergic eye drops: In the event of lid ptosis, alpha-adrenergic eye 
drops such as apraclonidine 0.5% can be used. Oxymetazoline, Upneeq, 0.1% 
has been FDA approved for the treatment of eyelid ptosis. These drops stimulate
the Müller muscle, a smooth muscle that assists in elevating the eyelid, thereby 
providing a temporary lift to the drooping eyelid. These drops can be used until 
the ptosis resolves.
Naphcon-A, Naphazoline/Pheniramine, is another over the counter option. This 
class of drug is known as sympathomimetic amines. There are no comparative 
clinical trials examining the benefits of any of the medications with each other. 
2. Wait for Toxin to Wear Off: Botulinum toxin effects are temporary, and the 
ptosis will resolve naturally as the effects of the toxin wear off, typically within 4-6
weeks.
Pearls in Botulinum Toxin 
Cosmetic Injection
As health care providers, we are always seeking to refine our skills and improve 
patient outcomes. This chapter will provide you with valuable insights and pearls 
of wisdom for administering botulinum toxin injections for cosmetic purposes. 
The Power of Touch
The human hand is an incredible tool. Use your hands to feel the face and 
identify the muscles causing visible wrinkles. This tactile approach will guide you 
to the precise injection site. Always inject a relaxed face, not a face where the 
muscle is contracted. Contracted muscles can distort your landmarks and lead to
less than optimal results.
Marking the Territory
Until you become proficient, use a marking pen or a white eyeliner pencil to mark
your injection sites. However, be sure to place the marks below where you will 
inject. Injecting into a mark on the face is akin to tattooing someone. 
Landmarks: More Than Skin Deep
Many landmarks are bony, not just on the skin’s surface. Do not rely solely on 
surface skin landmarks as your reference. Understanding the underlying 
anatomy is crucial for successful injections.
Complications: Be Prepared
Complications can occur as soon as 48 hours or as late as 7 days post-injection 
and may persist for up to 4 – 8 weeks. Most complications are almost always 
temporary. In your practice, you are likely to experience a complication. Be 
prepared for it. Good hand holding and patient reassurance that the complication 
is temporary will appease most patients. In some cases, offering a money-back 
refund can eliminate tension and potential headaches.
Documentation: Before and After Photos
Always obtain before and after photos. This is essential documentation to resolve
any complaints. It also provides a visual record of the treatment’s effectiveness.
Reinjection: Patience is Key
Reinjection should be done no earlier than one week after the first injection if the 
patient perceives no desired effect. Sometimes, it takes a week until a patient 
sees the effects. Patience is key.
Comfort Measures: EMLA and Ice Packs
Application of topical EMLA anesthetic or cold ice pack will help alleviate patient 
discomfort and injection fears. These simple measures can significantly improve 
the patient experience.
Pre and Post Injection Instructions
Please become familiar with our standard Pre and Post injection instructions. 
Your patients will ask you about them. Compliance with these instructions will 
reduce complications and improve outcomes.
Botulinum Toxin Pricing
Botulinum toxin injections are a significant investment for both the provider and 
the patient. Understanding the pricing structure is crucial to ensure a profitable 
practice and to provide clear and transparent information to patients.
Pricing Structure: Per Area, Per Syringe, or Per Unit?
There are different approaches to pricing botulinum toxin injections, and the 
choice often depends on the provider’s preference and the standard practice in 
their region. Some practices charge per area or per syringe, often using about 20
units per “area” or “syringe”. However, all manufacturers of botulinum toxin prefer
the “per unit” pricing model. This approach provides patients with knowledge of 
the units they are receiving, promoting transparency and consistency in 
treatment. 
Setting Your Prices
When setting your prices, it’s recommended to research your local market. Call 
local competitors and inquire about their pricing. If they charge per area, ask how
many units they use per area. 
As a general guide, here are some typical pricing ranges across the U.S.:
– Dermatologist/Plastic Surgeons: 150-200% higher than manufacturer purchase
price
– Average pricing: 100-150% higher than manufacturer purchase price
– Competitive pricing: 75-100% higher than manufacturer purchase price
Remember, these are just guidelines. Your pricing should reflect your expertise, 
the quality of your service, and your local market conditions.
Legal Considerations
It’s worth noting that purchasing any botulinum toxin products from outside the 
U.S., such as Canada, is illegal. The FDA has strict regulations on the import of 
medications, and non-compliance can lead to serious legal consequences.
Additional Pearls
– Transparency is key: Always be upfront with your patients about the cost of 
their treatment. This includes the number of units they will receive and the total 
cost.
– Document everything: Keep a record of the number of units used for each 
patient and each treatment area. This can help you track your usage and costs, 
and can also be useful in case of any disputes.
– Adjust as needed: Don’t be afraid to adjust your prices as needed based on 
changes in your costs, market conditions, or the value you provide.
Botulinum Toxin Marketing
Marketing is a crucial aspect of any successful medical practice, and this is 
especially true for practices offering botulinum toxin injections. The following 
strategies can help you effectively market your services and attract new patients.
Understanding Your Target Market
Before you begin marketing your services, it’s important to understand who your 
target market is. Botulinum toxin injections are popular among women aged 35 to
50 years old, but this can vary depending on your location and the specific 
services you offer. Understanding your target market will allow you to tailor your 
marketing efforts to the needs and interests of these potential patients.
Branding and Collaboration
Improving the branding of your botulinum toxin services can significantly increase
your bookings. This includes creating a professional and appealing logo, using 
consistent colors and fonts across all marketing materials, and developing a 
unique selling proposition that sets you apart from competitors.
Collaborating with influencers and local businesses can also be an effective way 
to drive interest in your services. This could involve partnering with a local fitness
center or spa, or working with a popular local blogger or social media influencer 
to promote your services.
Online Marketing
Having a strong online presence is essential in today’s digital age. This includes 
having a professional and user-friendly website, as well as active profiles on 
relevant social media platforms. Search engine optimization (SEO) and pay-per-
click (PPC) advertising can also be effective ways to increase your online 
visibility and attract new patients.
Collecting email addresses from existing patients and using email marketing 
campaigns can also be a powerful way to keep your services top of mind and 
encourage repeat bookings.
Traditional Media Advertising
While online marketing is crucial, don’t overlook the potential of traditional media 
advertising. This could include print ads in local newspapers or magazines, radio 
ads, or even television commercials. The best platforms for your practice will 
depend on your target market and local media landscape.
Customer Service and Experience
Providing excellent customer service is crucial for retaining patients and 
attracting new ones. This includes everything from the initial phone call or email 
inquiry, to the consultation and treatment process, to follow-up care.
Offering a unique patient experience can also set your practice apart. This could 
involve offering additional services, such as skincare consultations or massage, 
or creating a relaxing and luxurious treatment environment.
Education and Promotions
Educating potential patients about the benefits of botulinum toxin injections, and 
addressing common concerns or misconceptions, can help to build trust and 
interest in your services.
Offering promotions or discounts can also be an effective way to attract new 
patients. This could involve offering a discount for first-time patients, or a special 
promotion for existing patients who refer a friend.
Remember, marketing is not a one-time effort but an ongoing process. Regularly 
evaluating and adjusting your marketing strategies based on their effectiveness 
and changes in the market can help to ensure your practice’s success.
For more detailed strategies and tailored advice, consider consulting with our 
internal marketing specialist or taking advantage of resources offered by 
botulinum toxin manufacturers.
For more information about Comprehensive Guide to Botulinum Toxin Injection 
Training, contact us at [email protected] or call us at (212) 
470-8059.
Statement of Responsibility
Cosmetic Medical Training recognizes that many of the techniques and 
recommendations are for procedures that are considered off-label use.  Our 
recommendations are based on many textbooks, published articles, seminars, 
and practical knowledge and experience.  The authors have attempted to 
maintain up to date knowledge and information in this training manual with the 
current standard of care.  However, due to the continuing flow of new research 
and information relating to the drugs being used in this course, we recommend 
that you check with the manufacturer for any changes in the package inserts, 
warnings, and precautions.  All information and tools presented within this site 
are intended for educational purposes. We do not guarantee that the information 
will be completely accurate and up to date; therefore the authors will not be held 
responsible for any errors, omissions, or inaccuracies published.  Application of 
the knowledge is ultimately the responsibility of the practitioner.
The owners, authors, and any participants disclaim all liability or loss in 
conjunction with any content provided here. We disclaim any liability for products 
or services recommended including defective products or direct, indirect, special,
incidental, or consequential damages, arising out of the use or the inability to use
the materials/information published.
Originally published at  Botox Training Little Rock